ADIL Adial Pharmaceuticals: Company Short-Term Debt

Corporate emblem and logo of Adial Pharmaceuticals, Inc. (ADIL)

Adial Pharmaceuticals specializes in alcohol addiction therapy, leveraging a network of rehabilitation centers and the drug AD04 for individuals with a genetic predisposition. This price chart demonstrates the asset's dynamics, with a metric of 0.00. The company is currently facing a liquidity shortage due to testing costs in the absence of sales. Simultaneously, Adial Pharmaceuticals is minimizing risks by developing personalized treatments for various addictions.

Adial (ADIL) - Company Short-Term Loans and Borrowings from 07/04/2022 to 10/29/2026

Summary analytical data breakdowns for Adial Pharmaceuticals Inc. (ADIL)

- stock price and consensus target price:
Stock Price Adial|ADIL - Consensus Target
- company stock capitalization data:
Market Value Adial Pharmaceuticals, Inc.|ADIL - Total Enterprise Value
- shareholders' equity book value data:
Accounting Value per Share Adial Pharmaceuticals|ADIL - Accounting Value of Company|Market Capitalization to Book Value Ratio adialpharma.com|ADIL - Total Asset Value of Company
- debt and liquidity details:
Total Debt to Capital Adial Pharmaceuticals|ADIL - Long-Term Debt to Capital|Short-Term Debt to Equity Adial|ADIL - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Adial Pharmaceuticals, Inc.|ADIL - Company Long-Term Liabilities|Company Short-Term Debts Adial Pharmaceuticals|Quick Ratio adialpharma.com
- earnings and valuation multiples indicators:
ADIL - Company Profit
General company analysis:ADIL - adialpharma.com
Manufactured products of Adial

Under cost control conditions during clinical trials of Adial Pharmaceuticals (ADIL) drugs, monitoring liabilities for up to one year becomes critical for assessing solvency. By analyzing changes in the amount of short-term loans, an investor can track the repayment dynamics of term loans, allowing for the timely identification of liquidity gap risks and the determination of a safe entry point into the asset before a phase of high volatility occurs.

Competitor analysis

Indivior - Company Short-Term Debts|Collegium Pharma (COLL) - Company Current Liabilities|Cronos (CRON) - Company Short-Term Debt|Short-Term Debt Canopy Growth Corp. (CGC)|Company Current Liabilities HITI|ACB: Company Short-Term Loans and Borrowings|Company Short-Term Debts ACHV|SKYE: Current Liabilities|Company Short-Term Debts ANEB (Anebulo)|Company Short-Term Debts InterCure Ltd INCR|NTRB - Company Short-Term Debt|Company Short-Term Loans and Borrowings NSRX (Nasus Pharma Ltd)|igcinc.us (IGC) - Company Short-Term Debt|Company Current Liabilities MIRA Pharmaceuticals, Inc.|FLGC (Flora Growth Corporation) - Company Short-Term Debts|Company Short-Term Debts IMC|Company Short-Term Debts ARTL|ensysce.com - Company Short-Term Indebtedness|Company Short-Term Debts TTNP (Titan Pharmaceuticals, Inc.)|Short-Term Debt Volume Greenlane Holdings, Inc. (GNLN)|InMed Pharma - Company Short-Term Debts|AKAN - Company Short-Term Debts|Enveric Biosciences (ENVB) - Company Short-Term Debt|BGXX (Bright Green Corporation) - Company Short-Term Debt|Company Current Liabilities HPCO